1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: Coagulation Factors

Competitor Analysis: Coagulation Factors

  • May 2013
  • -
  • La Merie Publishing
  • -
  • 158 pages

Product description

The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 20012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. Projects hvae rapidly progressed in clinical trials and several of them are already under regulatory review.

Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and human plasma-derived products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.

The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific product portoflios and R&D pipelines of coagulation factors.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Coagulation Factors
Table of Contents

• Sales of Recombinant Coagulation Factors for Hemophilia in 2012
• Human Plasma-Derived Coagulation Factor VIII Concentrates
• Recombinant Coagulation Factor VIII
• Human Plasma-Derived Coagulation Factor IX
• Recombinant Coagulation Factor IX
• Human Plasma-Derived Factor VII
• Recombinant Coagulation Factor VII
• Human Plasma-Derived Coagulation Factor Concentrates for Willebrand Disease
• Recombinant Human von Willebrand Factor (vWF)
• Human Plasma-Derived Fibrinogen
• Recombinant Human Fibrinogen
• Human Plasma-Derived Factor XI
• Human Plasma-Derived Factor X
• Recombinant Human Factor X
• Human Plasma-Derived Factor XIII
• Recombinant Human Factor XIII
• Alternative Procoagulants and Adjuncts
• Human Plasma-Derived Prothrombin Complex Concentrates
• Gene Therapy of Hemophilia
• Topical Human Plasma-Derived Fibrinogen and Thrombin Products
• Topical Plasma-Derived Thrombin Products
• Topical Recombinant Human Factor II (Prothrombin)
• Alternative Topical Hemostats
• Corporate Coagulation Factor Product Portfolios and RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016

Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials ...

Factor VIII Inhibitors -Pipeline Insights, 2016

Factor VIII Inhibitors -Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “Factor VIII Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Factor VIII Inhibitors. The ...

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...


Download Unlimited Documents from Trusted Public Sources

Global Blood Disease Statistics

  • October 2016
    68 pages
  • Blood Disease  

    Factor VIII  

  • World  

View report >

Global Biopharmaceutical Statistics

  • September 2016
    25 pages
  • Biopharmaceutic...  

  • Australia  

    World  

    Oceania  

View report >

Protein and Enzyme Industry in Poland

  • July 2016
    222 pages
  • Protein  

    Enzyme  

    Biotechnology  

  • Poland  

View report >

Global Therapy Market

9 months ago

Related Market Segments :

Factor VIII
Protein

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.